Overview

Isotretinoin for Proliferative Vitreoretinopathy

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Proliferative vitreoretinopathy (PVR), or secondary scarring on and around the retina, is an important cause of retinal re-detachment. The purpose of this study is to evaluate the effect of oral isotretinoin, which inhibits the growth of cells responsible for proliferative vitreoretinopathy (PVR), on recurrent retinal detachment.
Phase:
Phase 4
Details
Lead Sponsor:
Wills Eye
Treatments:
Isotretinoin